Boston Scientific Corporation (BSX) is gaining investor attention, including Marshall Wace LLP, which holds nearly $792 ...

Boston Scientific’s BSX fourth-quarter 2024 performance was driven by its robust expansion of operations across different geographies outside the United States. The company’s impressive strategic ...

With no differences between single or dual antiplatelet therapy or anticoagulants at 6 months, an RCT is warranted for ...